Elevation Oncology Inc (NASDAQ:ELEV) — Market Cap & Net Worth
Market Cap & Net Worth: Elevation Oncology Inc (ELEV)
Elevation Oncology Inc (NASDAQ:ELEV) has a market capitalization of $21.63 Million ($21.63 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #24883 globally and #5238 in its home market, demonstrating a -3.95% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Elevation Oncology Inc's stock price $0.37 by its total outstanding shares 59252900 (59.25 Million). Review Elevation Oncology Inc (ELEV) financial obligations to assess the company's total debt and financial obligations.
Elevation Oncology Inc Market Cap History: 2021 to 2025
Elevation Oncology Inc's market capitalization history from 2021 to 2025. Data shows change from $356.70 Million to $21.63 Million (-57.05% CAGR).
Index Memberships
Elevation Oncology Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.00% | #714 of 976 |
|
NASDAQ Composite
IXIC
|
$41.27 Trillion | 0.00% | #2344 of 3165 |
Weight: Elevation Oncology Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Elevation Oncology Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Elevation Oncology Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ELEV by Market Capitalization
Companies near Elevation Oncology Inc in the global market cap rankings as of June 18, 2026.
Key companies related to Elevation Oncology Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
Elevation Oncology Inc Historical Marketcap From 2021 to 2025
Between 2021 and today, Elevation Oncology Inc's market cap moved from $356.70 Million to $ 21.63 Million, with a yearly change of -57.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $21.63 Million | -35.12% |
| 2024 | $33.34 Million | +4.77% |
| 2023 | $31.82 Million | -43.47% |
| 2022 | $56.29 Million | -84.22% |
| 2021 | $356.70 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Elevation Oncology Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $21.63 Million USD |
| MoneyControl | $21.63 Million USD |
| MarketWatch | $21.63 Million USD |
| marketcap.company | $21.63 Million USD |
| Reuters | $21.63 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Elevation Oncology Inc
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. It's lead candidate is EO-3021, an antibody-drug conjugate (ADC) comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 monoclonal antibody (mAb) site-specifically conjugated with a cleavable link… Read more